Drug Overview

Peg pei cholesterol lipopolymer encased il 12 dna plasmid vector imnn 001 (IMNN-001) (previously known in research as GEN-1) is a highly innovative, experimental cancer medicine. It belongs to a modern class of treatments called Immunotherapy and gene therapy. Unlike standard chemotherapy that attacks all fast-growing cells, this medicine is designed to deliver special DNA instructions directly to the area around the tumor, teaching your body’s own immune system how to fight the cancer. Because it is currently being tested in clinical trials, it is not yet available at standard pharmacies or hospitals for general public use.

Generic Name: PEG-PEI-cholesterol lipopolymer-encased IL-12 DNA plasmid vector (IMNN-001)
US Brand Names: None (Experimental drug)
Drug Class: IL-12 Gene-Mediated Immunotherapy
Route of Administration: Intraperitoneal (IP) Infusion (Given as a liquid directly into the abdominal cavity through a special port or tube)
FDA Approval Status: Not FDA Approved (Strictly limited to clinical trials, though it has received “Fast Track” and “Orphan Drug” designations from the FDA to speed up its development for ovarian cancer).

What Is It and How Does It Work? (Mechanism of Action)

Peg pei cholesterol lipopolymer encased il 12 dna plasmid vector imnn 001 2

IMNN-001 is a specialized Immunotherapy that works as a localized gene delivery system. To understand how it works at the molecular level, it helps to break down its long name and look at how it interacts with your cells.

The Delivery System (PEG-PEI-cholesterol lipopolymer): To get DNA safely into a cell, it needs a protective bubble. This drug uses a microscopic capsule made of special fats and polymers. This capsule protects the medicine from being destroyed by the body and helps it merge easily with the outer walls of cells inside the abdomen.
The Payload (IL-12 DNA plasmid vector): Inside the protective bubble is a small, circular piece of DNA (a plasmid). This DNA is essentially an “instruction manual” for making a powerful immune-boosting protein called Interleukin-12 (IL-12).
The Cellular Factory: When the drug is infused into the belly, the bubbles enter local cells (including tumor cells and nearby tissue cells). The cells read the DNA instructions and start manufacturing large amounts of IL-12 right next to the cancer.
The Immune Attack: IL-12 is like a loud alarm bell for the immune system. It strongly activates the body’s cancer-fighting defender cells—specifically T-cells and Natural Killer (NK) cells. These awakened cells then recognize the tumor and destroy it. By producing IL-12 locally in the belly, the drug avoids the severe, dangerous side effects that happen when IL-12 is injected directly into the bloodstream.

FDA-Approved Clinical Indications

Because IMNN-001 is an investigational medicine, it has not yet received full approval from the United States Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for general public use.

Oncological Uses (Investigational Only):

Advanced Ovarian Cancer
Primary Peritoneal Cancer
Fallopian Tube Cancer

Non-oncological Uses:

None at this time.

Dosage and Administration Protocols

Because IMNN-001 is utilized primarily in clinical trials (such as the OVATION studies), the exact dosage is determined by the specific research rules. It is typically given alongside standard intravenous (IV) chemotherapy before a patient undergoes surgery.

Protocol Detail	Standard Trial Information
Standard Trial Dose	Often dosed at specific levels (e.g., 36 mg/m² up to 100 mg/m²) depending on the trial phase.
Frequency of Administration	Usually given once a week.
Infusion Time	Administered as a local infusion into the abdominal port, taking a short time, but requires preparation.
Treatment Cycle	Commonly given weekly during the cycles of “neoadjuvant” (pre-surgery) chemotherapy.
Hepatic (Liver) Adjustment	General clinical trial guidelines require patients to have healthy liver function to participate.
Renal (Kidney) Adjustment	General clinical trial guidelines require healthy kidney function; exact adjustments are protocol-specific.

Note: Dosing is highly specific to the clinical trial rules and must be managed by a specialized oncology team.

Clinical Efficacy and Research Results

Recent clinical trial data (published between 2020 and 2025) has focused heavily on the OVATION 2 study, a Phase 2 trial testing IMNN-001 in patients with newly diagnosed advanced ovarian cancer.

Surgical Success Rates: A primary goal of giving IMNN-001 before surgery is to shrink the cancer enough so surgeons can remove it completely. In recent trial updates, patients receiving IMNN-001 alongside standard chemotherapy showed promising improvements in “R0 resection rates” (meaning the surgeon could find and remove 100% of the visible tumor) compared to patients receiving chemotherapy alone.
Survival and Progression: In mid-2024, data from the OVATION 2 study indicated encouraging trends in Overall Survival (OS) for patients receiving the immunotherapy, suggesting the treatment may help patients live longer by delaying the time it takes for the cancer to return or worsen.
Tumor Microenvironment: Biopsies taken during these trials prove that the drug successfully changes the area around the tumor from “cold” (hidden from the immune system) to “hot” (filled with active, cancer-killing T-cells).

Safety Profile and Side Effects

Because IMNN-001 is given locally into the abdomen, it generally avoids the widespread, severe side effects associated with IV immunotherapies. However, because it involves an abdominal catheter and immune activation, it does have specific side effects.

Black Box Warning: There is currently no FDA “Black Box Warning” because the drug is experimental and unapproved.

Common Side Effects (Occurs in >10% of patients)

Abdominal pain, cramping, or fullness (often due to the fluid being pumped into the belly)
Feeling unusually tired or weak (Fatigue)
Low-grade fever or chills (a sign the immune system is waking up)
Upset stomach (Nausea)
Mild diarrhea or constipation

Serious Adverse Events

Catheter Complications: The port or tube in the abdomen can become blocked, infected, or leak, requiring medical intervention or removal.
Overactive Immune Reactions: Though rare due to the localized delivery, strong immune-stimulating drugs can sometimes cause systemic inflammation.

Management Strategies

For Abdominal Discomfort: The care team may warm the infusion fluid slightly to body temperature to reduce cramping. They can also provide pain relievers before the procedure.
For Catheter Care: Nurses will strictly monitor and clean the abdominal port to prevent infections. Patients are taught how to keep the site clean at home.
For Fever and Chills: Over-the-counter medicines like acetaminophen can be used to manage flu-like symptoms caused by the immune response.

Research Areas

The research behind IMNN-001 is deeply connected to the future of advanced Immunotherapy. Ovarian cancer is notoriously difficult to treat because it builds a “shield” that keeps immune cells out. By using a gene-delivery system to force local cells to pump out IL-12, IMNN-001 breaks down this shield. Researchers are currently exploring how to combine this local gene therapy with other systemic immunotherapies (like immune checkpoint inhibitors). The idea is that IMNN-001 will act as the “spark” to light the fire inside the tumor, allowing other immune-boosting drugs or even engineered cell therapies to easily find the cancer and destroy it completely.

Patient Management and Practical Recommendations

Patient safety is the absolute highest priority during a clinical trial. Healthcare teams follow rigorous rules to protect patients receiving investigational gene therapies.

Pre-treatment Tests to be Performed

Catheter Placement and Check: A minor surgical procedure to place the port into the abdomen, followed by imaging to ensure fluid flows safely into the belly cavity without blockages.
Comprehensive Blood Panel: To check the health of the liver, kidneys, and blood cell counts before combining this treatment with standard chemotherapy.
Tumor Markers and Imaging: Baseline CA-125 blood tests and CT/PET scans to measure the exact size of the tumors before starting.

Precautions During Treatment

Port Care: The abdominal port is a direct line into your body. It must be kept meticulously clean and dry to prevent dangerous internal infections.
Monitor for Infection: Because you are also receiving standard chemotherapy, your immune system will fluctuate. Watch closely for signs of infection.

“Do’s and Don’ts” List

DO tell your doctor immediately if you develop a fever of 100.4°F (38°C) or higher.
DO report any redness, swelling, or leaking fluid around your abdominal port immediately.
DO wear comfortable, loose-fitting clothing to your infusion appointments to accommodate the extra fluid in your belly.
DON’T take baths, use hot tubs, or go swimming if you have an active abdominal port, as this can cause severe infections. Stick to showers as instructed by your nurse.
DON’T take any new over-the-counter medicines, herbal supplements, or vitamins without asking your oncology team first.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not substitute for professional medical advice, diagnosis, or treatment. IMNN-001 (GEN-1) is an investigational drug and is not approved by the FDA, EMA, or other global regulatory bodies for commercial use outside of clinical trials. Always consult with your oncologist or a qualified healthcare provider regarding your specific medical condition, clinical trial eligibility, and available, approved treatment options.